Verastem reports 86% 6-month OS rate in RAMP 205 pancreatic cancer trial; starts VS-7375 Phase 2

Verastem, Inc.

6-month OS rate 86%, ORR 52%, and 83% tumor shrinkage in RAMP 205 RP2D cohort (n=29).
9 patients remain on treatment; median follow-up 9.8 months; no new safety signals.
First patient dosed in TARGET-D 201 Phase 2 registration trial of VS-7375 (KRAS G12D) in second-line mPDAC.
PanCAN provided $3.8M Therapeutic Accelerator Award in 2022 for RAMP 205 research.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.